 Loma Linda, CA, June 30, 2020 GLOBE NEWSWIRE -- via NEWMEDIAWIRE -- Aditx Therapeutics, Inc. the Company ADTX, a life sciences company developing technologies specifically focused on improving the health of the immune system through immune reprogramming and monitoring, today announced the pricing of its initial public offering of 1,226,668 units at an offering price of 9.00 per unit. The Series A warrants permit the holder to purchase one share of common stock at an exercise price of 9.00 and expire after 5 years. The Series B warrants contain an exchange feature that will permit the holder to exchange the warrant into shares of common stock on a one-for-one basis any time commencing the earlier of 10 days from the IPO or the time when 10 million of volume is traded in the common stock, if the closing stock price of the common stock on the date of exercise is below the exercise price of the Series B warrant. 